Search Results 2231-2240 of 20214 for Receptor

  1. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  2. Publications - Eapen K. Jacob, M.D. - Mayo Clinic

    Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain ...

  3. Brain Tumor Program - Clinical trials

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  4. Brain Tumor Program - Clinical trials

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  5. A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma - Mayo Clinic

    receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the. PK trigger) prior to planned start of specified study therapy. - Known ...

  6. Tradipitant (oral route) - Side effects & dosage - Mayo Clinic

    Tradipitant is used to prevent vomiting caused by motion sickness. Tradipitant is a substance P/neurokinin 1 (NK1) receptor antagonist. It works by blocking the ...

  7. The Kronos Early Estrogen Prevention Study (KEEPS) - Mayo Clinic

    Use of selective estrogen receptor modulators (SERMs) such as Raloxifene, Tamoxifen, etc. Self reported, known BrCa positive genotype (KEEPS will not screen ...

  8. A Study to Compare Cabozantinib versus Sunitinib to Treat Metastatic Variant Histology Renal Cell Carcinoma Patients - Mayo Clinic

    ... receptor tyrosine kinase inhibitors. The patient may have received treatment with immune checkpoint therapy including nivolumab as a single agent or ...

  9. Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer - Mayo Clinic

    Tumors > 2.0 cm (irrespective of hormonal receptor status) or > 1.0 cm if ER-negative and PR-negative disease. ER/PgR determination; HER-2 positive (pre-entry ...

  10. Study Comparing CB-839 with Cabozantinib vs. Cabozantinib with Placebo in Patients with Metastatic Renal Cell Carcinoma - Mayo Clinic

    Small molecule receptor tyrosine kinase inhibitor (TKI) therapy (including investigational) within 2 weeks or 5 half-lives, whichever is longer;; Any type of ...